A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
A Phase I/II, Open-label, Dose-Escalating Study With a Proof of Concept Cohort to Evaluate the Safety, Tolerability and Efficacy of ARGX-110 in Combination With Azacytidine in Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)
Sponsor: Janssen Research & Development, LLC
This PHASE1/PHASE2 trial investigates Leukemia, Myeloid, Acute and Myelodysplastic Syndromes and is currently completed. Janssen Research & Development, LLC leads this study, which shows 33 recorded versions since 2016 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Change History
33 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2023 — Sep 2023 [monthly]
Completed PHASE1_PHASE2
Status: Active Not Recruiting → Completed
▶ Show 28 earlier versions
-
Nov 2022 — Jan 2023 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2022 — Nov 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jul 2022 — Sep 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
May 2022 — Jul 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2022 — May 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2022 — Apr 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Feb 2022 — Mar 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2022 — Feb 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Dec 2021 — Jan 2022 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Nov 2021 — Dec 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2021 — Nov 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Sep 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jun 2021 — Sep 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Mar 2021 — Jun 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Aug 2020 — Oct 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2020 — Aug 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
-
Apr 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1_PHASE2
Status: Recruiting → Active Not Recruiting
-
Feb 2019 — Apr 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Dec 2018 — Feb 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2018 — Dec 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Aug 2018 — Sep 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Sep 2017 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
-
Jul 2017 — Sep 2017 [monthly]
Recruiting PHASE1_PHASE2
-
Feb 2017 — Jul 2017 [monthly]
Recruiting PHASE1_PHASE2
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Janssen Research & Development, LLC
- OncoVerity, Inc.
- argenx
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
- • Aarau, Switzerland
- • Bern, Switzerland
- • Marseille, France
- • Paris, France
- • Pierre-Bénite, France
- • Toulouse, France
- • Zurich, Switzerland